- Home
- PPBT vs MULN Comparison
PPBT vs MULN Comparison
Compare PPBT & MULN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- PPBT
- MULN
- Stock Information
- Founded
- PPBT 2010
- MULN 2014
- Country
- PPBT Israel
- MULN United States
- Employees
- PPBT N/A
- MULN N/A
- Industry
- PPBT Biotechnology: Pharmaceutical Preparations
- MULN Auto Manufacturing
- Sector
- PPBT Health Care
- MULN Consumer Discretionary
- Exchange
- PPBT Nasdaq
- MULN Nasdaq
- Market Cap
- PPBT 6.3M
- MULN 6.5M
- IPO Year
- PPBT N/A
- MULN N/A
- Fundamental
- Price
- PPBT $2.34
- MULN $0.62
- Analyst Decision
- PPBT Strong Buy
- MULN
- Analyst Count
- PPBT 1
- MULN 0
- Target Price
- PPBT $33.00
- MULN N/A
- AVG Volume (30 Days)
- PPBT 29.4K
- MULN 8.0M
- Earning Date
- PPBT 08-15-2025
- MULN 08-11-2025
- Dividend Yield
- PPBT N/A
- MULN N/A
- EPS Growth
- PPBT N/A
- MULN N/A
- EPS
- PPBT N/A
- MULN N/A
- Revenue
- PPBT N/A
- MULN $8,931,612.00
- Revenue This Year
- PPBT N/A
- MULN N/A
- Revenue Next Year
- PPBT N/A
- MULN N/A
- P/E Ratio
- PPBT N/A
- MULN N/A
- Revenue Growth
- PPBT N/A
- MULN 2136.62
- 52 Week Low
- PPBT $2.00
- MULN $0.59
- 52 Week High
- PPBT $13.95
- MULN $154,200,000.00
- Technical
- Relative Strength Index (RSI)
- PPBT 41.27
- MULN 20.72
- Support Level
- PPBT $2.30
- MULN $1.62
- Resistance Level
- PPBT $2.45
- MULN $1.64
- Average True Range (ATR)
- PPBT 0.14
- MULN 0.91
- MACD
- PPBT -0.03
- MULN 152.97
- Stochastic Oscillator
- PPBT 16.58
- MULN 0.66
About PPBT Purple Biotech Ltd.
Purple Biotech Ltd is a clinical-stage company focused on advancing first-in-class therapies to overcome tumor immune evasion and drug resistance, and to create treatments for people with cancer. Its oncology pipeline includes NT219: A dual inhibitor, small molecule that simultaneously targets Insulin Receptor Substrate 1 and 2 (IRS1/2) and Signal Transducer and Activator of Transcription (STAT3), two survival signal transduction pathways driving the development of cancer drug resistance. and CM24: is a humanized monoclonal antibody designed to block the interactions of Carcinoembryonic Antigen Related Cell Adhesion Molecule 1 (CEACAM1), a glycoprotein that plays a key role in immune regulation, cell adhesion, and tumor progression, CAPTN3.
About MULN Mullen Automotive Inc.
Mullen Automotive Inc is engaged in manufacturing electric vehicles and building energy solutions. Its portfolio of vehicles is predominantly comprised of commercial trucks and other electric vehicles and includes; Mullen Class 1 Cargo Van, Mullen Three, Bollinger B4 Chassis Cab, and Mullen I-GO. The company's operating segments are Bollinger which derives maximum revenue, and Mullen Commercial.